Trinity Biotech PLC
TRIB- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000888721
No open-market purchases or sales by Trinity Biotech PLC insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $379.5K in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Trinity Biotech PLC changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 22 | 20 | −2 |
| Shares | 9.02M | 7.29M | −1.72M (−19.1%) |
| Value | $9.56M | $8.92M | −$638.0K (−6.7%) |
New holders (3)
Institutions that held Trinity Biotech PLC at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Aristides Capital LLC | 240,679 | $295.0K | 0.23% |
| Two Sigma Securities, LLC | 11,049 | $14.0K | 0.00% |
| BlackRock Inc. | 992 | $1.00K | 0.00% |
Sold out (5)
Institutions that held Trinity Biotech PLC at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Highbridge Capital Management LLC | 1,151,610 | $1.22M |
| Millennium Management LLC | 42,365 | $45.0K |
| Virtu Financial LLC | 37,926 | $40.0K |
| Wells Fargo & Company | 837 | $1.00K |
| UBS Group AG | 701 | $1.00K |